
|Videos|August 16, 2017
Dr. Choyke Discusses Screening in Prostate Cancer
Author(s)Peter Choyke, MD, FACR
Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.
Advertisement
Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.
Conducting random biopsies do not make any sense in a modern world, says Choyke. The best strategy to identify high-grade cancer is MRI, he adds.
In terms of when to operate or radiate, practitioners find that the answer is not perfect—there is a learning curve. A lot of this has to do with good communication between the urologist and radiologist, says Choyke.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5



































